Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation

2022; Elsevier BV; Volume: 45; Linguagem: Inglês

10.1016/j.nano.2022.102595

1549-9642

Mônica Josiane Rodrigues‐Jesus, Marianna Teixeira de Pinho Favaro, Aléxia Adrianne Venceslau-Carvalho, Maria Fernanda de Castro‐Amarante, Bianca da Silva Almeida, Mariângela de Oliveira Silva, Robert Andreata‐Santos, Cecília Gomes Barbosa, Samantha Carvalho Maia Brito, Lúcio H. Freitas-Júnior, Silvia Beatriz Boscardin, Luís Carlos de Souza Ferreira,

Bacterial Infections and Vaccines

The development of safe and effective vaccine formulations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represents a hallmark in the history of vaccines. Here we report a COVID-19 subunit vaccine based on a SARS-CoV-2 Spike protein receptor binding domain (RBD) incorporated into nano-multilamellar vesicles (NMV) associated with monophosphoryl lipid A (MPLA). The results based on immunization of C57BL/6 mice demonstrated that recombinant antigen incorporation into NMVs improved antibody and T-cell responses without inducing toxic effects under both in vitro and in vivo conditions. Administration of RBD-NMV-MPLA formulations modulated antigen avidity and IgG subclass responses, whereas MPLA incorporation improved the activation of CD4+/CD8+ T-cell responses. In addition, immunization with the complete vaccine formulation reduced the number of doses required to achieve enhanced serum virus-neutralizing antibody titers. Overall, this study highlights NMV/MPLA technology, displaying the performance improvement of subunit vaccines against SARS-CoV-2, as well as other infectious diseases.